Start
Dec 18, 2012 - 16:30
End
Dec 18, 2012 - 17:30
Venue
Library Department of Chemical Engineering.
Event Type
Speaker
Dr. BARRY C. BUCKLAND PROFESSOR UNIVERSITY COLLEGE LONDON
Title
BIOPROCESS ENGINEERING CHALLENGES FOR THERAPEUTIC PROTEIN AND VACCINES
About the speaker: PhD in Biochemical Engineering at University College London obtained in 1974. Joined the Merck Research Laboratories (MRL) in 1980 and built a world class Bioprocess R&D group. Leader of process development of all biologically made product candidates within the MRL pipeline and manufacture of Clinical Supplies during the past 20 years. Products developed within this timeline include MEVACOR® ZOCOR® IVOMEC® CANCIDAS® RECOMBIVAX HB® VAQTA® VARIVAX® COMVAX®. ROTATEQ® (Rotavirus vaccine) ZOSTAVAX® (shingles vaccine) and GARDASIL® (HPV vaccine). External awards and appointments include being elected to the National Academy of Engineering in 1997 and Fellow of University College London in 1998. Awards include the Donald Medal UK Institute of Chemical Engineering in 2002 Prix Galien award: Member of team to receive Vaccine Award for Gardasil® in 2007 Merck Board of Directors Award for leading process development for licensure of four (4) new vaccines in 2007. Chaired two International Conferences on Cell Culture (Cell Culture Engineering IV and Cell Culture Engineering V) and co-chaired the first three International Conferences on Metabolic Engineering. Co-chaired the first two International Conferences on Vaccine Technology. Author or co-author of over 70 papers. Visiting Professor at University College London for past 15 years. In October 2008 named by AIChE as one of the "One Hundred Chemical Engineers of the Modern Era" (defined as from World War II to Present) as part of the AIChE Centennial Celebration in Philadelphia USA and also awarded Marvin Johnson Award by ACS (American Chemical Society) for lifetime contribution to Biotechnology. Awarded PhRMA Discoverer of the Year award in April 2009 for development of the Merck HPV vaccine (along with Eliav Barr and Kathrin Jansen). Starting in May 2009; CEO BiologicB. Since this time have provided consultancy worldwide to a number of companies and not-for-profit institutions in all areas of Biologics including Vaccines and Therapeutic Proteins. Member of Board of Directors for Ancora and Mucosis. Chair of Board for a not-for-profit organization Engineering Conferences International. Continue as Visiting Professor at University College London. Founder and Board Member of start-up company Enumeral Biomedical. Head Bioprocess Development at Protein Sciences.